人民财讯12月10日电，重药控股（000950）12月10日公告，公司下属控股子公司重庆医药(集团)股份有 限公司持有重庆药友制药有限责任公司(简称"药友制药")38.67%股权。12月9日，药友制药与上海复星 医药（600196）产业发展有限公司及辉瑞共同签订许可协议，药友制药就口服小分子胰高血糖素样肽-1 受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品(以下简称"许可产品")授予辉瑞于许可区 域(即全球范围)及领域(即人类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化 权利；就本次许可，药友制药将有权依约获得(其中包括)不可退还的首付款15000万美元及基于许可产 品临床、商业化进展获得开发里程碑付款至多35000万美元。 ...

Core Insights - The collaboration between Fosun Pharma and Pfizer marks a significant milestone in the competitive landscape of GLP-1 therapies, highlighting Fosun's innovative capabilities in small molecule drug development [3][8][10] Group 1: Transaction Details - On December 9, Fosun Pharma announced a licensing agreement with Pfizer for its orally administered small molecule GLP-1 receptor agonist YP05002, granting Pfizer global rights for development, production, and commercialization [4][5] - Fosun Pharma will receive an upfront payment of up to $150 million, with potential milestone payments totaling up to $1.935 billion, along with tiered royalties post-approval [4][5] Group 2: Market Context - The GLP-1 market is experiencing intense competition, with major pharmaceutical companies actively pursuing next-generation therapies. Sales of existing GLP-1 products like semaglutide and tirzepatide have reached $25.462 billion and $24.837 billion respectively in the first three quarters of the year, indicating a strong market demand [6][7] - The collaboration signifies Fosun Pharma's recognition in the global market, as it aligns with the trend of multinational corporations seeking innovative GLP-1 solutions [5][6] Group 3: Strategic Implications - Fosun Pharma's chairman emphasized that this partnership is a key step in the company's strategy for innovation and internationalization, aiming to address unmet clinical needs in obesity and metabolic diseases [5][8] - The deal is part of a broader trend where Fosun Pharma has secured multiple business development transactions in 2023, totaling approximately $4 billion, showcasing its diverse research capabilities [9][10]

责任编辑：栎树 12月10日，复星医药A股一度涨近5%报28.8元，H股一度涨近7%报22.94港元。消息面上，公司昨晚公 告，控股子公司药友制药与辉瑞于2025年12月9日签订《许可协议》，药友制药就口服小分子胰高血糖 素样肽-1受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品授予辉瑞于全球范围及领域(人 类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化权利。 港股频道更多独家策划、专家专栏，免费查阅>> 药友制药将有权获得不可退还的首付款1.5亿美元及至多3.5亿美元的开发里程碑款项。此外，基于许可 产品的年度净销售额达成情况，辉瑞将向药友制药支付至多15.85亿美元的销售里程碑款项。该协议自 2025年12月9日起生效。 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% [2][5]. Core Insights - The company has entered a significant licensing agreement with Pfizer for its proprietary oral small molecule GLP-1R agonist, YP05002, which is currently in Phase I clinical trials in Australia. This agreement includes an upfront payment of $150 million and potential milestone payments totaling up to $385 million, along with sales milestone payments that could reach $1.585 billion [6][7]. - The licensing deal is seen as a recognition of the company's R&D capabilities and is expected to enhance the valuation of its pipeline. The total deal value is approximately $2.085 billion, which is a significant milestone for the company [7]. - The upfront payment is projected to significantly boost the company's net profit, estimated to account for 38% of the 2024 net profit, with expectations of recognition in 2026 [7]. - The profit forecast has been revised upwards, with expected net profits of RMB 33.2 billion, RMB 46.8 billion, and RMB 47.7 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 19.8%, 40.8%, and 19.1% [7][8]. - The company is expected to maintain a low valuation with H-share PE ratios of 16X, 11X, and 11X for the years 2025, 2026, and 2027, indicating a favorable long-term outlook [7]. Financial Summary - The company’s projected net profit for 2025 is RMB 33.2 billion, with a year-on-year increase of 19.8% [8]. - The earnings per share (EPS) for 2025 is expected to be RMB 1.24, with a growth rate of 19.54% compared to the previous year [8]. - The projected revenue for 2025 is RMB 44.867 billion, with a slight increase from RMB 41.067 billion in 2024 [10].

Group 1 - The core viewpoint of the article highlights that Fosun Pharma has signed a $2.1 billion collaboration agreement with Pfizer for its preclinical small molecule GLP-1 drug, YP05002, positioning it favorably in the GLP-1 market [1] - The report from Credit Lyonnais indicates that Pfizer's active participation and long-term strategy in the GLP-1 field make the financial terms of the collaboration reasonable compared to similar licensing agreements [1] - Following the renewed market interest in the GLP-1 sector, it is anticipated that Fosun Pharma's stock price will respond positively, although this may increase competitive pressure for domestic peers expanding overseas [1] Group 2 - Credit Lyonnais has raised its profit forecasts for Fosun Pharma, increasing the net profit estimates for 2025 to 2027 by 1%, 2.4%, and 1.9% respectively, reflecting the financial impact of the collaboration [1] - The target price for Fosun Pharma's H-shares has been raised from HKD 29.6 to HKD 31.6, while the target price for A-shares has been increased from CNY 40.2 to CNY 42.4, maintaining an "outperform" rating [1]

Core Insights - Pfizer has made a significant investment in acquiring rights to a GLP-1 receptor agonist developed by Chinese company药友制药, indicating a strategic move into the obesity treatment market, which is currently experiencing high demand due to the rising prevalence of obesity globally [2][3] Group 1: Transaction Details - The agreement grants Pfizer exclusive global rights for the development, use, production, and commercialization of the GLP-1 drug, with a total potential transaction value of $2.085 billion, including an upfront payment of $150 million and milestone payments [3] - This transaction aligns with similar deals in the industry, where Chinese pharmaceutical companies have engaged in licensing agreements for GLP-1 drugs, typically valued around $2 billion [3] Group 2: Market Context - The GLP-1 class of drugs has become increasingly popular for treating diabetes and obesity, with the highest global sales recorded for two GLP-1 drugs in the first three quarters of 2025 [2] - The market for pet obesity is also being recognized, with Pfizer's agreement explicitly mentioning animal indications, highlighting the potential for GLP-1 drugs in treating obesity in pets [4] Group 3: Competitive Landscape - Pfizer has faced challenges in developing its own GLP-1 drugs, having terminated three oral GLP-1 candidates between 2023 and 2025, with only one currently in clinical phase II [3] - The competitive landscape includes other companies like Okava, which is conducting clinical trials for a GLP-1 drug aimed at pets, indicating a growing interest in this niche market [4]

Core Viewpoint - Fosun Pharma's stock price increased by 5.96% to HKD 22.76 following the announcement of a licensing agreement with Pfizer for the development of the oral GLP-1 receptor agonist YP05002 [2][6]. Group 1: Licensing Agreement - Fosun Pharma's subsidiary,药友制药, and Fosun Pharma Industry signed a licensing agreement with Pfizer on December 9, 2025, granting Pfizer exclusive rights to develop, use, manufacture, and commercialize YP05002 globally for all human and animal indications [2][6]. - As part of the agreement,药友制药 will receive a non-refundable upfront payment of USD 150 million and up to USD 350 million in milestone payments based on clinical and commercialization progress of the licensed product [2][6]. Group 2: Product Details - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, aimed at treating type 2 diabetes, obesity, and related diseases [3][7]. - The drug works by activating GLP-1 receptors to promote insulin secretion, reduce glucagon secretion, inhibit gastric emptying, and suppress appetite, thereby aiding in weight management and treating metabolic disorders [3][7]. - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [3][7].

Group 1 - Fosun Pharma (02196) opened over 4% higher, currently up 4.19% at HKD 22.38, with a trading volume of HKD 8.5715 million [1] - The company announced a licensing agreement with Pfizer on December 9, 2025, allowing Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist (including YP05002) globally for all human and animal indications [1] - Under this agreement, Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of USD 150 million and up to USD 350 million in milestone payments based on the clinical and commercialization progress of the licensed product [1] Group 2 - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, designed to treat type 2 diabetes, obesity, and related diseases by promoting insulin secretion and reducing glucagon secretion [2] - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2] - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [2]

扬子晚报网12月10日讯(记者范晓林)今天是周三，昨天安记食品（603696）6连板，龙洲股份 美股三大指数收盘涨跌不一摩根大通跌超4% 美股三大指数收盘涨跌不一，道指跌0.37%，纳指涨0.13%，标普500指数跌0.09%，谷歌、博通、特斯 拉涨超1%，Meta跌超1%。贵金属、加密货币板块涨幅居前，泛美白银涨超11%，美洲白银公司涨超 7%，Hut8、金田涨超4%，Strategy涨超2%。生物技术、减肥药、多元化银行板块走低，硕迪生物、摩 根大通跌超4%，安进跌超2%，礼来、辉瑞跌超1%。 2连板厦门空港：筹划收购兆翔科技100%股权 厦门空港（600897）(600897.SH)发布股票交易异常波动公告称，根据厦门市规划部署，厦门翔安国际 机场计划于2026年底正式投入使用，厦门空港所运营的厦门高崎国际机场将同步关闭，届时不再作为民 用运输机场使用。为积极应对厦门高崎国际机场转场后上市公司机场主业持续经营存在的不确定性，同 时积极响应国家鼓励上市公司向新质生产力方向转型升级的号召，公司正在筹划以自有资金收购公司控 股股东厦门翔业集团有限公司(以下简称"翔业集团")的全资子公司厦门兆翔智能科技有限公司 ...

Group 1 - China's CPI and PPI data for November will be released [3] - The 2025 China Platinum Group Metals Market Annual Conference is scheduled to be held in Sanya [3] - The 20th China IDC Industry Annual Conference will take place from December 10 to 11 [3] Group 2 - U.S. stock indices closed mixed, with the Dow down 0.37%, Nasdaq up 0.13%, and S&P 500 down 0.09% [6] - Major tech stocks like Google, Broadcom, and Tesla rose over 1%, while Meta fell over 1% [6] - The Nasdaq Golden Dragon China Index dropped 1.37%, with most Chinese concept stocks declining [6] Group 3 - International oil prices fell, with WTI crude down 0.87% at $58.37 per barrel and Brent crude down 0.66% at $62.08 per barrel [7] - Spot silver prices broke the $60 mark, reaching a historical high of $60.83 per ounce, currently at $60.71, up 4.5% [7] - Spot gold rose 0.5% to $4211.27 per ounce [7] Group 4 - China's crude oil production is expected to reach 215 million tons in 2025, a historical high [10] - During the 14th Five-Year Plan period, China has added 105 million tons of new crude oil capacity, with offshore oil contributing over 60% of the new production [10] Group 5 - The Hainan Free Trade Port successfully completed its first international transshipment "change order" business [11] - A batch of clothing goods from Milan, Italy, was transshipped through Haikou Meilan International Airport to Hong Kong [11] Group 6 - Fujian Province encourages companies like CATL and Xingyun Electronics to develop electric ship infrastructure [12] - The plan aims to promote the electric ship industry as an advanced sector in Fujian, focusing on charging and swapping facilities [12] Group 7 - The Ministry of Public Security has publicly announced a wanted list for 100 fugitives involved in telecom network fraud [13] - This initiative aims to combat cross-border telecom fraud and protect citizens' property rights [13] Group 8 - Trump announced that Nvidia's sales of H200 chips to China will require 25% of revenue to be paid to the U.S. government [13] - This move is expected to create jobs and maintain U.S. leadership in the AI sector [13] Group 9 - The Chinese government is preparing for elections, with President Zelensky requesting security guarantees from the U.S. and Europe [14] - The elections could be held within 60 to 90 days if security is assured [14] Group 10 - Xiaomi has initiated a series of personnel adjustments in key operational positions across its mobile, automotive, and home appliance sectors [28] - These changes may indicate a strategic shift in the company's business layout [28]